糖尿病肾病纤维化机制和中医药治疗研究进展
Research Progress on the Mechanism of Fibrosis in Diabetic Kidney Disease and the Treatment of Traditional Chinese Medicine
DOI: 10.12677/jcpm.2025.43403, PDF,   
作者: 徐 航, 王 帅：黑龙江省中医药科学院研究生院，黑龙江 哈尔滨；迟继铭*：黑龙江省中医医院南岗院区肾五科，黑龙江 哈尔滨
关键词: 肾纤维化；糖尿病肾病；中医药治疗；Renal Fibrosis； Diabetic Kidney Disease； Traditional Chinese Medicine Treatment
摘要: 肾纤维化是以肾组织损伤，炎症浸润，细胞外基质(ECM)沉积和上皮细胞间充质转化产生瘢痕为主要特点的重要病变表现。其具体的发病机制错综复杂，但糖尿病肾病(DKD)是诱发肾纤维化的主要病因之一。纤维化是所有慢性肾脏疾病(CKD)迁延变化的最终途径，现已被认为是慢性肾脏疾病进展的独立风险因子，研究肾纤维化的发病机制，对于遏制和改善各种原因导致的慢性肾脏疾病具有重大意义。本文以糖尿病肾病相关性肾纤维化分子因子机制和中医药成果展开论述，期望为临床延缓慢性糖尿病肾病纤维化进程提供一定的理论依据。
Abstract: Renal fibrosis is an important pathological manifestation characterized by renal tissue injury, inflammatory infiltration, extracellular matrix (ECM) deposition, and epithelial-mesenchymal transition leading to scar formation. Its specific pathogenesis is complex and intricate, but diabetic kidney disease (DKD) is one of the main causes of renal fibrosis. Fibrosis is the ultimate pathway of chronic kidney disease (CKD) progression, and is now considered an independent risk factor for the progression of chronic kidney disease. Studying the pathogenesis of renal fibrosis is of great significance for controlling and improving chronic kidney disease caused by various reasons. This article discusses the molecular mechanism of renal fibrosis associated with diabetic kidney disease and the achievements of traditional Chinese medicine, hoping to provide a certain theoretical basis for delaying the progression of chronic diabetic kidney disease fibrosis in clinical practice.
文章引用：徐航, 王帅, 迟继铭. 糖尿病肾病纤维化机制和中医药治疗研究进展[J]. 临床个性化医学, 2025, 4(3): 739-746. https://doi.org/10.12677/jcpm.2025.43403

参考文献

[1] Tanase, D.M., Gosav, E.M., Anton, M.I., Floria, M., Seritean Isac, P.N., Hurjui, L.L., et al. (2022) Oxidative Stress and NRF2/KEAP1/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives. Biomolecules, 12, Article 1227. [Google Scholar] [CrossRef] [PubMed]
[2] Meng, X.M., Nikolic-Paterson, D.J. and Lan, H.Y. (2016) TGF-β: The Master Regulator of Fibrosis. Nature Reviews Nephrology, 12, 325-338.
[3] Meng, X.M., Tang, P.M., Li, J., et al. (2015) TGF-β/Smad Signaling in Renal Fibrosis. Frontiers in Physiology, 6, Article 82.
[4] Park, C.H. and Yoo, T.H. (2022) TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis. Pharmaceuticals, 15, Article 1485.
[5] Dou, L. and Jourde-Chiche, N. (2019) Endothelial Toxicity of High Glucose and Its By-Products in Diabetic Kidney Disease. Toxins, 11, Article 578.
[6] Segerer, S., Nelson, P.J. and Schlöndorff, D. (2000) Chemokines, Chemokine Receptors, and Renal Disease from Basic Science to Pathophysiologic and Therapeutic Studies. Journal of the American Society of Nephrology, 11, 152-176. [Google Scholar] [CrossRef] 
[7] Ito, Y., Aten, J., Bende, R.J., et al. (1998) Expression of Connective Tissue Growth Factor in Human Renal Fibrosis. Kidney International, 53, 853-61. [Google Scholar] [CrossRef] [PubMed]
[8] Ostendorf, T., Boor, P., van Roeyen, C.R., et al. (2014) Platelet-Derived Growth Factors (PDGFs) in Glomerular and Tubulointerstitial Fibro Sis. Kidney International Supplements, 4, 65-69.
[9] Moriya, J., Wu, X., Zavala-Solorio, J., Ross, J., Liang, X.H. and Ferrara, N. (2014) Platelet-derived Growth Factor C Promotes Revascularization in Ischemic Limbs of Diabetic Mice. Journal of Vascular Surgery, 59, 1402-1409. [Google Scholar] [CrossRef] [PubMed]
[10] Buhl, E.M., Djudjaj, S., Babickova, J., Klinkhammer, B.M., Folestad, E., Borkham-Kamphorst, E., et al. (2016) The Role of PDGF-D in Healthy and Fibrotic Kidneys. Kidney International, 89, 848-861. [Google Scholar] [CrossRef] [PubMed]
[11] Costache, M.I., Ioana, M., Iordache, S., Ene, D., Costache, C.A. and Săftoiu, A. (2015) VEGF Expression in Pancreatic Cancer and Other Malignancies: A Review of the Literature. Romanian Journal of Internal Medicine, 53, 199-208. [Google Scholar] [CrossRef] [PubMed]
[12] Rogers, N.M., Thomson, A.W. and Isenberg, J.S. (2012) Activation of Parenchymal CD47 Promotes Renal Ischemia-Reperfusion Injury. Journal of the American Society of Nephrology, 23, 1538-1550. [Google Scholar] [CrossRef] [PubMed]
[13] Kramann, R., Wongboonsin, J., Chang-Panesso, M., Machado, F.G. and Humphreys, B.D. (2016) Gli1+ Pericyte Loss Induces Capillary Rarefaction and Proximal Tubular Injury. Journal of the American Society of Nephrology, 28, 776-784. [Google Scholar] [CrossRef] [PubMed]
[14] Ruiz-Llorente, L., Gallardo-Vara, E., Rossi, E., Smadja, D.M., Botella, L.M. and Bernabeu, C. (2017) Endoglin and Alk1 as Therapeutic Targets for Hereditary Hemorrhagic Telangiectasia. Expert Opinion on Therapeutic Targets, 21, 933-947. [Google Scholar] [CrossRef] [PubMed]
[15] Grignaschi, S., Sbalchiero, A., Spinozzi, G., Palermo, B.L., Cantarini, C., Nardiello, C., et al. (2022) Endoglin and Systemic Sclerosis: A Prisma-Driven Systematic Review. Frontiers in Medicine, 9, Article 964526. [Google Scholar] [CrossRef] [PubMed]
[16] Gerrits, T., Zandbergen, M., Wolterbeek, R., Bruijn, J.A., Baelde, H.J. and Scharpfenecker, M. (2020) Endoglin Promotes Myofibroblast Differentiation and Extracellular Matrix Production in Diabetic Nephropathy. International Journal of Molecular Sciences, 21, Article 7713. [Google Scholar] [CrossRef] [PubMed]
[17] Rahimi, Z. (2016) The Role of Renin Angiotensin Aldosterone System Genes in Diabetic Nephropathy. Canadian Journal of Diabetes, 40, 178-183. [Google Scholar] [CrossRef] [PubMed]
[18] 邹健, 田丰, 孙圣燕, 等. 肾素－血管紧张素系统与糖尿病肾病[J]. 人民军医, 2012, 55(1): 68-70.
[19] Zhang, C., Zhu, X., Li, L., Ma, T., Shi, M., Yang, Y., et al. (2019) A Small Molecule Inhibitor MCC950 Ameliorates Kidney Injury in Diabetic Nephropathy by Inhibiting NLRP3 Inflammasome Activation. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 12, 1297-1309. [Google Scholar] [CrossRef] [PubMed]
[20] Tang, S.C.W. and Yiu, W.H. (2020) Innate Immunity in Diabetic Kidney Disease. Nature Reviews Nephrology, 16, 206-222. [Google Scholar] [CrossRef] [PubMed]
[21] 张金鑫, 高绪霞, 马立萍. 炎症因子对糖尿病肾脏疾病作用的研究进展[J]. 中国糖尿病杂志, 2024, 32(10): 788-790.
[22] Maeda, Y., Inoguchi, T., Takei, R., Sawada, F., Sasaki, S., Fujii, M., et al. (2010) Inhibition of Chymase Protects against Diabetes-Induced Oxidative Stress and Renal Dysfunction in Hamsters. American Journal of Physiology-Renal Physiology, 299, F1328-F1338. [Google Scholar] [CrossRef] [PubMed]
[23] Duan, S., Sun, L., Nie, G., Chen, J., Zhang, C., Zhu, H., et al. (2020) Association of Glomerular Complement C4c Deposition with the Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes. Frontiers in Immunology, 11, Article 2073. [Google Scholar] [CrossRef] [PubMed]
[24] Su, H., Wan, C., Song, A., Qiu, Y., Xiong, W. and Zhang, C. (2019) Oxidative Stress and Renal Fibrosis: Mechanisms and Therapies. In: Advances in Experimental Medicine and Biology, Springer, 585-604. [Google Scholar] [CrossRef] [PubMed]
[25] Rhee, E.P. (2016) NADPH Oxidase 4 at the Nexus of Diabetes, Reactive Oxygen Species, and Renal Metabolism. Journal of the American Society of Nephrology, 27, 337-339. [Google Scholar] [CrossRef] [PubMed]
[26] Wu, X., Wang, H., Chen, H., Lin, H., Li, M., Yue, Z., et al. (2021) Overexpression of Smad7 Inhibits the TGF-β/Smad Signaling Pathway and EMT in Nphp1-Defective MDCK Cells. Biochemical and Biophysical Research Communications, 582, 57-63. [Google Scholar] [CrossRef] [PubMed]
[27] Schunk, S.J., Floege, J., Fliser, D. and Speer, T. (2020) Wnt-β-Catenin Signalling—A Versatile Player in Kidney Injury and Repair. Nature Reviews Nephrology, 17, 172-184. [Google Scholar] [CrossRef] [PubMed]
[28] Meurette, O. and Mehlen, P. (2018) Notch Signaling in the Tumor Microenvironment. Cancer Cell, 34, 536-548. [Google Scholar] [CrossRef] [PubMed]
[29] Wang, J.Y., Gao, Y.B., Zhang, N., et al. (2014) miR-21 Overexpression Enhances TGF-β1-Induced Epithelial-to-Mesenchymal Transition by Target Smad7 and Aggravates Renal Damage in Diabetic Nephropathy. Molecular and Cellular Endocrinology, 392, 163-172.
[30] 张小燕, 王若楠, 孙嘉星, 等. 内皮间质转化在肾纤维化中的作用及机制研究进展[J]. 空军军医大学学报, 2022, 43(7): 359-364.
[31] Livingston, M.J., Ding, H., Huang, S., Hill, J.A., Yin, X. and Dong, Z. (2016) Persistent Activation of Autophagy in Kidney Tubular Cells Promotes Renal Interstitial Fibrosis during Unilateral Ureteral Obstruction. Autophagy, 12, 976-998. [Google Scholar] [CrossRef] [PubMed]
[32] Lenoir, O., Jasiek, M., Hénique, C., Guyonnet, L., Hartleben, B., Bork, T., et al. (2015) Endothelial Cell and Podocyte Autophagy Synergistically Protect from Diabetes-Induced Glomerulosclerosis. Autophagy, 11, 1130-1145. [Google Scholar] [CrossRef] [PubMed]
[33] 魏琪, 王菊宁, 刘利敏. 慢性缺氧通过激活缺氧诱导因子1α/microRNA-96通路诱导小管上皮细胞自噬异常参与肾间质纤维化[J]. 肾脏病与透析肾移植杂志, 2024, 33(1): 22-28.
[34] 杨林燕, 陈洁, 侯世杰, 等. 白芍总苷对糖尿病肾病小鼠肾纤维化及RhoA/ROCK1信号通路的影响[J/OL]. 中医学报, 1-11.
http://kns.cnki.net/kcms/detail/41.1411.R.20240829.0926.012.html, 2025-06-24.
[35] 唐洗敏, 杨勇琴, 杨琇雯, 等. 地龙提取物蚓激酶对SD大鼠肾间质纤维化的改善作用[J]. 平顶山学院学报, 2024, 39(5): 123-128.
[36] 袁玲, 王蕾, 王宏, 等. 淫羊藿苷调控TGF-β1诱导的DNA高甲基化抑制5/6肾切除大鼠肾间质肌成纤维细胞增殖研究[J]. 药物评价研究, 2024, 47(12): 2770-2777.
[37] 沈鑫蕾, 朱清如, 余文凯, 等. 盐炙车前子调控肾小管上皮-间充质转化改善肾纤维化的机制研究[J]. 中国中药杂志, 2025, 50(5): 1195-1208.
[38] 吴朋烊, 赵铃, 李秋月, 等. 三白草酮对UUO 小鼠肾组织纤维化的抑制作用及其机制[J]. 中国实验动物学报, 2024, 32(10): 1270-1280.